Effect of Cinnamon Extract on Insulin Resistance in Polycystic Ovary Syndrome (Eccentric)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00970541|
Recruitment Status : Terminated (Recruitment)
First Posted : September 2, 2009
Last Update Posted : October 28, 2019
|Condition or disease||Intervention/treatment||Phase|
|Polycystic Ovary Syndrome Insulin Resistance||Dietary Supplement: Cinnamon Supplementation Dietary Supplement: Placebo (wheat flour)||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||8 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Phase 1 Study That Will Compare 12 Weeks of Supplementation With Cinnamon Extract on the Action of Insulin and Blood Sugar (Glucose) With 12 Weeks of Supplementation With a Placebo.|
|Study Start Date :||August 2009|
|Actual Primary Completion Date :||June 2013|
|Actual Study Completion Date :||June 2013|
Active Comparator: Cinnamon Supplementation
A 500mg (consumed as two, 250mg capsules) of cinnamon extract (Cinnamon Bark P.E> 20:1) will be consumed before meals, three times per day.
Dietary Supplement: Cinnamon Supplementation
1, 3, or 6g of cinnamon per day for 40 days
Other Name: The bark of Cinnamoni Cassae
Placebo Comparator: Placebo
A 500 mg placebo (wheat flour) will be consumed before meals, three times per day.
Dietary Supplement: Placebo (wheat flour)
1, 3, or 6g of placebo per day for 40 days
Other Name: 500mg placebo (wheat flour) will be cnsumed before meals, three times per day.
- Insulin sensitivity measured by the euglycemic hyperinsulinemic clamp [ Time Frame: 6 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00970541
|United States, Louisiana|
|Pennington Biomedical Research Center|
|Baton Rouge, Louisiana, United States, 70808|
|Principal Investigator:||Leanne Redman, PhD||Pennington Biomedical Research Center|